SCHEMBL593337

SCHEMBL593337

CCCCCCCCCCCCCC/C=C/OC(=O)CCC(=O)O/C=C/CCCCCCCCCCCCCC

nearest known ligand 0.53

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PPARG P37231 5/20 0.53
PPARD Q03181 5/20 0.53
PPARA Q07869 5/20 0.53
F7 P08709 4/20 0.53
F3 P13726 4/20 0.53
TERT O14746 3/20 0.53
PTPN1 P18031 3/20 0.53
HSD17B10 Q99714 3/20 0.53
FABP4 P15090 3/20 0.53
CYP1A2 P05177 2/20 0.53
MAPT P10636 2/20 0.53
CYP2C19 P33261 2/20 0.53
BLM P54132 2/20 0.53
FAAH O00519 2/20 0.53
KMT2A Q03164 2/20 0.53
LMNA P02545 2/20 0.53
ALOX15 P16050 2/20 0.53
DUSP3 P51452 2/20 0.53
CYP19A1 P11511 2/20 0.53
PTGS1 P23219 2/20 0.53

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL499986 1.00 PPARG (0.53) PPARGPPARDPPARAF7F3
SCHEMBL258564 1.00 PPARG (0.53) PPARGPPARDPPARAF7F3
SCHEMBL6255727 1.00 PPARG (0.53) PPARGPPARDPPARAF7F3
SCHEMBL544208 1.00 PPARG (0.53) PPARGPPARDPPARAF7F3
SCHEMBL41307 1.00 PPARG (0.53) PPARGPPARDPPARAF7F3
SCHEMBL1317133 1.00 PPARG (0.53) PPARGPPARDPPARAF7F3
SCHEMBL3883983 1.00 PPARG (0.53) PPARGPPARDPPARAF7F3
SCHEMBL3883975 1.00 PPARG (0.53) PPARGPPARDPPARAF7F3
SCHEMBL4638672 1.00 PPARG (0.53) PPARGPPARDPPARAF7F3
SCHEMBL7571463 1.00 PPARG (0.53) PPARGPPARDPPARAF7F3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 186 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20220249351-A1 COSMETIC NOEVIR CO., LTD. (JP) 2022-08-11 US claimed
CN-113924081-A Cosmetic preparation 株式会社诺薇雅 2022-01-11 CN claimed
EP-3383947-B1 RELEASE AID ECOLAB USA INC (US) 2021-06-16 EP claimed
WO-2019058338-A1 METHODS TO PRODUCE LIQUID OXYGEN EMULSION AND ADMINISTER INTRAVASCULAR LIQUID OXYGEN AODH LIFESCIENCES PRIVATE LIMITED (IN) 2019-03-28 WO claimed
EP-3251657-A1 TOPICAL AQUEOUS SPRAY COMPOSITIONS OF HALOBETASOL Sun Pharmaceutical Industries Limited (IN) 2017-12-06 EP claimed
US-20170340649-A1 TOPICAL AQUEOUS SPRAY COMPOSITIONS OF HALOBETASOL SUN PHARMACEUTICAL INDUSTRIES LIMITED (IN) 2017-11-30 US claimed
EP-1129694-B1 Use of components for modifying the physico-chemical properties of the skin and/or the mucous membrane as agents for preventing or reducing the adhesion of micro-organisms thereon OREAL (FR) 2005-09-07 EP claimed
US-20040047885-A1 Use of compounds which make it possible to modify the physicochemical properties of the skin and/or the mucous membranes as agents preventing or reducing the adhesion of microorganisms to the latter L'OREAL 2004-03-11 US claimed
US-6461625-B1 OIL IN WATER NANOEMULSION HAVING OIL GLOBULES WITH SPECIFIED SIZE, SURFACTANT SELECTED FROM ALKOXYLATED ALKENYL SUCCINATES OR ALKOXYLATED ALKENYL SUCCINATES OF GLUCOSE OR METHYLGLUCOSE, OIL HAVING SPECIFIED MOLECULAR WEIGHT L'OREAL (FR) 2002-10-08 US claimed
EP-1025898-B1 Nanoemulsion from alkoxylated alkenyl succinates or alkoxylated alkenyl succinates of glucose and its cosmetic, dermatologic, ophtalmologic and/or pharmaceutical uses OREAL (FR) 2002-01-23 EP claimed
US-20010051170-A1 Use of compounds which make it possible to modify the physicochemical properties of the skin and/or the mucous membranes as agents preventing or reducing the adhesion of microorganisms to the latter L'OREAL (FR) 2001-12-13 US claimed
EP-1025898-A1 Nanoemulsion from alkoxylated alkenyl succinates or alkoxylated alkenyl succinates of glucose and its cosmetic, dermatologic, ophtalmologic and/or pharmaceutical uses L'OREAL (FR) 2000-08-09 EP claimed
EP-0550879-B1 Process for coating cellulosic membranes AKZO NOBEL NV (NL) 1997-03-12 EP claimed
US-12582715-B1 Cancer radiation therapy with biocompatible quantum dots for simultaneous dose enhancement and counter-metastasis CREIGHTON UNIVERSITY (US) 2026-03-24 US disclosed
US-12516260-B2 Fuel compositions SHELL USA, INC. (US) 2026-01-06 US disclosed
US-20250042940-A1 14-3-3 TARGETING PEPTIDES FOR CANCER TREATMENT CREIGHTON UNIV (US) 2025-02-06 US disclosed
EP-1025898-A1 Nanoemulsion from alkoxylated alkenyl succinates or alkoxylated alkenyl succinates of glucose and its cosmetic, dermatologic, ophtalmologic and/or pharmaceutical uses L'OREAL (FR) 2000-08-09 EP disclosed
EP-0070191-B2 DETERGENT ADDITIVES AND DETERGENT COMPOSITIONS CONTAINING THEM UNILEVER PLC (GB) 1990-05-09 EP disclosed
US-4611087-A (METH)ACRYLIC ESTERS; (METH)ALLYL ESTERS; REACTIVE SURFACTANTS KAO CORPORATION (JP) 1986-09-09 US disclosed
EP-0070191-B1 DETERGENT ADDITIVES AND DETERGENT COMPOSITIONS CONTAINING THEM UNILEVER PLC (GB) 1985-12-04 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-12582715-B1 Cancer radiation therapy with biocompatible quantum dots for simultaneous dose enhancement and counter-metastasis EPCAM, ROS1, DCX PPARG 3591/4885PPARD 3786/4885PPARA 4570/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.